Dr. Krishna Mohan Ella, Chief Executive Officer, India Biotech, said that the development of the Covid-19 vaccine is moving in a positive direction and the next one month is crucial. The company has formed a joint venture with the University of Wisconsin, the Indian Council of Medical Research (ICMR) and Thomas Jefferson University in Philadelphia to develop a vaccine for Covid-19.
Speaking to IANS, Mohan said: “The development of the vaccine is moving in a positive direction. The next month is very important. I am a scientist and I believe in science.”
Against the background of the statement, The Serum Institute of India said in response to questions about India Biotech’s plans to produce the vaccine, which it plans to produce a million million doses of a possible Covid-19 vaccine by the end of the year, Ella said. Is working extremely hard to develop the vaccine.
Good progress in the COVID-19 vaccine
He expressed satisfaction with the progress made so far in research related to vaccine development, but stressed that “in science, things can change.” “If things don’t go well, I won’t talk to you … We can’t comment on a very important stage, the dose number (such as Serum Institute), etc.,” Mohan added.
According to the ICMR, human trials can begin in as little as 6 months. When asked about the introduction of the human test for the vaccine, Mohan said: “Let’s move on to science. I can’t comment on the beginning of the human test.”
He added, “We are working very hard on the vaccine, which will benefit the people.”
The next month is important
Noting that the world media is closely monitoring the development of the vaccine, Mohan refrained from commenting on the progress so far and any specific target set for next month.
On the second day, India witnessed 8,390 cases in 24 hours. The total number of cases of coronavirus on Monday was 1,90,535. India has emerged as the 7th worst cove-hit country in the world, surpassing France and Germany. There are at least 93,322 active cases and 91,819 have been cured. The recovery rate in the country is now 46.19 percent, and the death rate is 2.883 percent.
In May, Mohan said India Biotech was collaborating with Thomas Jefferson University to develop a new vaccine for Covid-19 using an inactive rubbish vector platform. He further added that it has established the earliest evidence of conception when used for other epidemic infectious diseases.
Mohan said the agency is committed to global public health and will be involved in ending the development of vaccines, including clinical trials to obtain commercial licenses.
(With IANS input)